• 1
    Cancer Research UK. 2012 []. Accessed 27 October 2013.
  • 2
    Kim MK, Jo H, Kong HJ, Kim HC, Kim JW, Kim YM, et al. Postoperative nomogram predicting risk of recurrence after radical hysterectomy for early-stage cervical cancer. Int J Gynecol Cancer 2010;20:15816.
  • 3
    Hirakawa M, Nagai Y, Inamine M, Ogawa K, Toita T, Murayama S, et al. Predictive factors of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol 2008;108:1269.
  • 4
    Anon. Topotecan (Hycamtin©) for the treatment of recurrent and stage IVB carcinoma of the cervix. Single Technology Appraisal (STA) Submission to the National Institute for Health and Clinical Excellence. London: GlaxoSmithKline, 2009.
  • 5
    Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000;78:18793.
  • 6
    Lim KC, Howells RE, Evans AS. The role of clinical follow up in early stage cervical cancer in South Wales. BJOG 2004;111:14448.
  • 7
    Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009;112:1049.
  • 8
    Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:52934.
  • 9
    Jover R, Lourido D, Gonzalez C, Rojo A, Gorospe L, Alfonso JM. Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol 2008;110 (3 Suppl 2):S559.
  • 10
    Scottish Intercollegiate Guidelines N. Management of Cervical Cancer. Edinburgh: NHS Quality Improvement Scotland, 2008.
  • 11
    Barrington S, Scarsbrook A. Evidence Based Indications for the Use of PET-CT in the United Kingdom 2012. London: The Royal College of Physicians and The Royal College of Radiologists, 2012.
  • 12
    Diagnostic Test Accuracy Working G. Handbook for DTA Reviews. 2012 []. Accessed 27 October 2013.
  • 13
    Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2010;3:25.
  • 14
    Reitsma JB, Glas AS, Rutges AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:98290.
  • 15
    Meads CA, Davenport CF. Quality assessment of diagnostic before-after studies: development of methodology in the context of a systematic review. BMC Med Res Methodol 2009;9:3.
  • 16
    Auguste P, Barton P, Meads C, Davenport C, Malysiak S, Kowalska M, et al. Evaluating PET–CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis. BJOG. doi: 10.1111/1471-0528.12460 (forthcoming).
  • 17
    Meads C, Auguste P, Davenport C, Malysiak S, Sundar S, Kowalska M, et al. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling. Health Technol Assess 2013;17:1323.
  • 18
    O'Hagan A, Buck CE, Daneschkkah A, Eiser JR, Garthwaite PH, Jenkinson DJ, et al. Uncertain judgements: eliciting expert's probabilties. Stat Pract 2006.
  • 19
    Amit A, Beck D, Lowenstein L, Lavie O, Bar S, Kedar Z, et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006;100:659.
  • 20
    Cetina L, Serrano A, Cantu-de-Leon D, Perez-Montiel D, Estrada E, Coronel J, et al. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. Rev Invest Clin 2011;63:22735.
  • 21
    Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol 2012;81:e81722.
  • 22
    Grisaru D, Almog B, Levine C, Metser U, Fishman A, Lerman H, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol 2004;94:6804.
  • 23
    Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K. Performance of FDG-PET-CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 2008;18:20407.
  • 24
    Mittra E, El-Maghraby T, Rodriguez CA, Quon A, Ross McDougal I, Gambhir SS, et al. Efficacy of 18F-FDG PET-CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2009;36:19529.
  • 25
    Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010;37:12708.
  • 26
    Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, et al. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2007;34:4729.
  • 27
    Minkyung Lee YL, Hwang KH, Choe W, Park CY. Usefulness of F-18 FDG PET/CT in assessment of recurrence of cervical cancer after treatment. Nucl Med Mol Imaging 2011;45:1116.
  • 28
    Weber TM, Sostman HD, Spritzer CE, Ballard RL, Meyer GA, Clark-Pearson DL, et al. Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging. Radiology 1995;194:1359.
  • 29
    Hatano K. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1999;45:63944.
  • 30
    Park DH, Kim KH, Park SY, Lee BH, Choi CW, Chin SY. Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography. Korean J Radiol 2000;1:515.
  • 31
    Heron CW, Husband JE, Williams MP, Dobbs J, Cosgrove DO. The value of CT in the diagnosis of recurrent carcinoma of the cervix. Clin Radiol 1988;39:501.
  • 32
    Walsh JW, Amendola MA, Hall DJ, Tisnado J, Goplerud DR. Recurrent carcinoma of the cervix: CT diagnosis. Am J Roentgenol 1981;136:11722.
  • 33
    Williams MP, Husband JE, Heron CW, Cherryman GR, Koslin DB. Magnetic resonance imaging in recurrent carcinoma of the cervix. Br J Radiol 1989;62:54450.
  • 34
    Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007;106:2934.
  • 35
    Boughanim M, Leboulleux S, Rey A, Pham CT, Zafrani Y, Duvillard P, et al. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol 2008;26:255861.
  • 36
    Chao A, Ho KC, Wang CC, Cheng HH, Lin G, Yen TC, et al. Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. Gynecol Oncol 2008;110:1728.
  • 37
    Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F]fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:216771.
  • 38
    Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003;44:34752.